To Compare the Outcome of Temporary Portocaval Shunt During Recipient Hepatectomy Versus No Shunt in Adult Elective Live Donor Liver Transplantation.

Sponsor
Institute of Liver and Biliary Sciences, India (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05385120
Collaborator
(none)
40
2
15.2

Study Details

Study Description

Brief Summary

Temporary portocaval Shunt during recipient hepatectomy improves intra operative parameters and morbidity in LDLT recipients

Condition or Disease Intervention/Treatment Phase
  • Procedure: Temporary Portocaval Shunt
N/A

Detailed Description

All patients satisfying the inclusion criteria, written informed consent will be taken and patients are randomized into intervention group ( Portocaval Shunt Group) and Non intervention group ( No Shunt Group).Patients from both the groups will be assessed for Hemodynamic parameters, Urine Output, Blood loss, blood products requirement , Duration of surgery during the procedure. They will be assessed for renal function, presence of sepsis, Morbidity, early graft dysfunction, ICU stay and total hospital stay in the post operative period.All patients will be followed up till discharge from hospital.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A Randomised Pilot studyA Randomised Pilot study
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
To Compare the Outcome of Temporary Portocaval Shunt During Recipient Hepatectomy Versus No Shunt in Adult Elective Live Donor Liver Transplantation- A Prospective Randomised Pilot Study
Anticipated Study Start Date :
May 25, 2022
Anticipated Primary Completion Date :
Jul 30, 2023
Anticipated Study Completion Date :
Aug 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group A-Shunt group

Patients who undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation

Procedure: Temporary Portocaval Shunt
In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.

No Intervention: Group B-No Shunt group

Patients who donot undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation

Outcome Measures

Primary Outcome Measures

  1. Blood Pressure between two groups at fixed time points [T0- At the beginning of the procedure]

    Systolic Blood pressure, Diastolic Blood Pressure and Mean Blood Pressure is measured in mmHg

  2. Ionotropes requirement between two groups at fixed time points [T0- At the beginning of the procedure]

    Noradrenaline and Vasopressin requirement in milliliter/hour

  3. Lactate level between two groups at fixed time points [T0- At the beginning of the procedure]

    Lactate levels are documented from Arterial Blood Gas analysis

  4. Blood Pressure between two groups at fixed time points [T1- During procedure- Before portocaval shunt formation]

    Systolic Blood pressure, Diastolic Blood Pressure and Mean Blood Pressure is measured in mmHg

  5. Ionotropes requirement between two groups at fixed time points [T1- During procedure- Before portocaval shunt formation]

    Noradrenaline and Vasopressin requirement in milliliter/hour

  6. Lactate level between two groups at fixed time points [T1- During procedure- Before portocaval shunt formation]

    Lactate levels are documented from Arterial Blood Gas analysis

  7. Blood Pressure between two groups at fixed time points [T2- During procedure- Just Before Reperfusion of graft liver]

    Systolic Blood pressure, Diastolic Blood Pressure and Mean Blood Pressure is measured in mmhg

  8. Ionotropes requirement between two groups at fixed time points [T2- During procedure- Just Before Reperfusion of graft liver]

    Noradrenaline and Vasopressin requirement in milliliter/hour

  9. Lactate level between two groups at fixed time points [T2- During procedure- Just Before Reperfusion of graft liver]

    Lactate levels are documented from Arterial Blood Gas analysis

  10. Blood Pressure between two groups at fixed time points [T3- During procedure- 5 minutes after reperfusion of graft liver]

    Systolic Blood pressure, Diastolic Blood Pressure and Mean Blood Pressure is measured in mmhg

  11. Ionotropes requirement between two groups at fixed time points [T3- During procedure- 5 minutes after reperfusion of graft liver]

    Noradrenaline and Vasopressin requirement in milliliter/hour

  12. Lactate level between two groups at fixed time points [T3- During procedure- 5 minutes after reperfusion of graft liver]

    Lactate levels are documented from Arterial Blood Gas analysis

  13. Blood Pressure between two groups at fixed time points [T4- During procedure- Before closure of abdomen]

    Systolic Blood pressure, Diastolic Blood Pressure and Mean Blood Pressure is measured in mmhg

  14. Ionotropes requirement between two groups at fixed time points [T4- During procedure- Before closure of abdomen]

    Noradrenaline and Vasopressin requirement in milliliter/hour

  15. Lactate level between two groups at fixed time points [T4- During procedure- Before closure of abdomen]

    Lactate levels are documented from Arterial Blood Gas analysis

  16. Blood loss between two groups during intraoperative period [During Procedure]

    Blood loss during the procedure is measured in milliliter

  17. Duration of surgery between two groups. [During Procedure]

    Duration between incision time to closure of abdomen is noted in minutes

  18. Increase in creatinine levels of Increase 1.5-1.9 times from baseline in the post op period. [Number of days post transplantation procedure (upto 45 days)]

    Serum Creatinine is measured in milligram per deciliter

  19. ≥0.3 mg/dl increase within 48 h or Urine output < 0.5 ml/kg/h for 6-12 h in the post op period. [Number of days post transplantation procedure (upto 45 days)]

    Serum Creatinine is measured in milligram per deciliter

  20. Urine output between two groups [During Transplantation procedure]

    Urine output during the transplantation procedure is measured in milliliter

Secondary Outcome Measures

  1. To compare tolerance to enteral feed between two groups [Number of days post transplantation procedure (upto 45 days)]

    Tolerance to NG feed is defined by absence of bloating, nausea, vomiting, abdominal distention or ileus

  2. Endotoxin levels [Levels of Serum endotoxin levels in pre op and 12 hours after surgery]

    Serum endotoxin levels increases in cases of bowel congestion and hemodynamic instability when portal vein is clamped during recipient hepatectomy

  3. Number of patients with Early allograft dysfunction [For 5 consecutive days after day 7]

    Early allograft dysfunction using criteria defined - total bilirubin >10 mg/dL, INR >1.6 and serum urea >100 mg/dL, for five consecutive days after day 7

  4. Incidence of Morbidity [Number of days post transplantation procedure (upto 45 days)]

    Morbidity is defined by Clavein Dindo Classification - >/=3. Sepsis as defined by Sepsis- 3 criteria, presence of 2 or more of the following 1.altered mentation, 2.respiratory rate ≥22 breaths/min 3.systolic blood pressure ≤100 mm Hg

  5. Incidence of sepsis [Number of days post transplantation procedure (upto 45 days)]

    Morbidity is defined by Clavein Dindo Classification - >/=3. Sepsis as defined by Sepsis- 3 criteria, presence of 2 or more of the following 1.altered mentation, 2.respiratory rate ≥22 breaths/min 3.systolic blood pressure ≤100 mm Hg

  6. Number of days of ICU stay [Number of days post transplantation procedure (upto 45 days)]

    Day patient shifted from ICU to ward is documented as total ICU stay. Day patient is discharged from hospital is documented for total hospital stay

  7. Number of days of hospital stay [Number of days post transplantation procedure (upto 45 days)]

    Day patient shifted from ICU to ward is documented as total ICU stay. Day patient is discharged from hospital is documented for total hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. All Adult LDLT Recipients at ILBS, New Delhi
Exclusion Criteria:
  1. Acute Liver Failure as an indication for transplant

  2. Pediatric transplants

  3. Presence of Yerdel grade III and grade IV Portal vein thrombosis

  4. Presence of significant portosystemic shunting (greater than 10mm) in pre operative period.

  5. Patients who have undergone TIPS procedure.

  6. Hypercoagulable states like Budd-Chiari syndrome

  7. Refusal to participate in the study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Institute of Liver and Biliary Sciences, India

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institute of Liver and Biliary Sciences, India
ClinicalTrials.gov Identifier:
NCT05385120
Other Study ID Numbers:
  • IEC/2021/91/MA04
First Posted:
May 23, 2022
Last Update Posted:
May 23, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institute of Liver and Biliary Sciences, India

Study Results

No Results Posted as of May 23, 2022